Advertisement
GSK vs JNJ
Which Stock Would AI Choose? GSK plc (GSK) vs. Johnson & Johnson (JNJ) Stock Comparison
Key Takeaways
- GSK is a UK-based pharma and vaccines company executing a cost-savings and pipeline acceleration plan, while JNJ is a diversified US healthcare giant spanning pharmaceuticals and medical technology (medtech).
- Both stocks remain supported by dividend income and strong pharmaceutical demand, but their near-term momentum has diverged in recent weeks.
- JNJ beat third-quarter earnings expectations but fell on slowing medtech growth, a large talc-related charge, and a modest guidance raise.
- GSK beat second-quarter estimates and launched a £1.9 billion savings program, though it faces an approaching HIV patent cliff.
- Relative performance and market positioning differ sharply: JNJ has posted strong year-to-date gains, while GSK has consolidated after a multi-year re-rating.
Introduction
Investors comparing GSK and JNJ are effectively weighing two distinct models within global healthcare: a focused UK pharmaceuticals and vaccines player against a diversified US healthcare conglomerate. This stock comparison matters to income-oriented investors, sector specialists, and traders evaluating relative performance and market positioning. Both companies generate dependable cash flow and defend meaningful dividends, yet they face different catalysts and risk profiles. Understanding how sentiment, pipeline momentum, and divisional execution differ between the two can help readers assess which profile aligns with their own outlook.
GSK Overview and Recent Performance
GSK (GSK plc, formerly GlaxoSmithKline) is a science-led healthcare company organized around Specialty Medicines, Vaccines, and General Medicines. Recent market activity has been shaped by a leadership transition: Luke Miels became chief executive at the start of 2026, succeeding Emma Walmsley, and has emphasized operational execution and research and development (R&D) acceleration.
In recent quarters, GSK delivered results modestly ahead of consensus, led by Specialty Medicines and Vaccines while General Medicines declined. The company unveiled a multi-year program targeting £1.9 billion in annual savings by 2029, with much of the benefit reinvested into a late-stage pipeline it now expects to support more than 20 Phase III trials in 2026. Sentiment has also been influenced by the discontinuation of the chronic-cough candidate camlipixant and an approaching patent cliff for its dolutegravir-based HIV franchise between 2028 and 2030. The stock has consolidated after a strong multi-year run, with its dividend yield remaining a central part of the investment case.
JNJ Overview and Recent Performance
JNJ (Johnson & Johnson) operates two principal segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). Its most recent quarterly report showed reported sales rising to roughly $25.4 billion, with adjusted earnings per share (EPS) above consensus. Pharmaceutical growth was the standout, driven by treatments such as Tremfya and Darzalex, which helped offset steep declines in the legacy product Stelara as it faces biosimilar competition.
However, recent stock behavior has been pressured by a slowdown in MedTech, where growth decelerated across several consecutive quarters amid international headwinds, including Middle East disruption, European budget constraints, and pricing pressure in China. A large one-time charge tied to a proposed talc litigation resolution also weighed on reported earnings, and the company indicated it is evaluating a potential spinoff of its orthopedics business. Despite strong year-to-date gains, JNJ shares pulled back following the update, reflecting investor focus on the softer device segment.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page offers a curated view of AI trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and basket of securities. Because not every bot suits every market environment, the Trending AI Robots section highlights only those currently best aligned with prevailing conditions. The available bots span a wide range of approaches and performance statistics, giving traders a way to compare historical results and risk parameters before engaging. Explore the Trending AI Robots page to see which strategies are currently standing out.
Head-to-Head Comparison
The clearest contrast between the two names is structural. GSK is a more concentrated play on branded pharmaceuticals and vaccines, with roughly half of its sales generated in the US. JNJ pairs its Innovative Medicine franchise with a large device business, creating diversification but also exposing shareholders to device-market and procedural-volume risks.
On growth drivers, GSK is leaning on oncology, HIV, and respiratory assets, while JNJ relies on oncology and immunology launches to offset Stelara erosion. Both companies are also actively reshaping their portfolios: GSK through cost savings and pipeline focus, and JNJ through acquisitions, collaborations, and a possible orthopedics separation. From a momentum standpoint, JNJ has delivered stronger recent share-price appreciation on a trailing-year basis, whereas GSK has trended sideways after a substantial prior advance. Risk factors differ accordingly: GSK faces concentrated patent-expiry exposure, while JNJ carries litigation and medtech cyclicality concerns.
Tickeron AI Verdict
Based on observable factors such as trend consistency, catalyst visibility, and relative positioning, Tickeron's AI would likely lean toward JNJ for its steadier trend structure and diversified cash flows, while recognizing that GSK presents a higher-yield, more pipeline-driven profile. The recent medtech deceleration and talc-related headline risk introduce near-term volatility for JNJ, just as the HIV patent cliff and pipeline execution risk temper enthusiasm for GSK. In probabilistic terms, the current setup appears more constructive for JNJ, though neither name shows a decisive, uncontested edge across all measures.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Hold and JNJ is a Hold.
GSK in upward trend: price may jump up because it broke its lower Bollinger Band on October 01, 2026
GSK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 40 cases where GSK's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GSK's RSI Oscillator exited the oversold zone, 16 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on GSK as a result. In 53 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on October 15, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in 31 of 46 cases over the following month. The odds of a continued upward trend are 67%.
Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 202 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
GSK moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for GSK entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.266) is normal, around the industry mean (19.199). P/E Ratio (15.948) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.037) settles around the average of (0.025) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 42 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
JNJ sees its Stochastic Oscillator recovers from oversold territory
On October 09, 2026, the Stochastic Oscillator for JNJ moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 50 instances where the indicator left the oversold zone. In 25 of the 50 cases the stock moved higher in the following days. This puts the odds of a move higher at over 50%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Indicator exited the oversold zone, 13 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 45%.
Following a +2.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 164 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
JNJ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JNJ as a result. In 36 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 43%.
JNJ moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for JNJ crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.
The Aroon Indicator for JNJ entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.710) is normal, around the industry mean (19.199). P/E Ratio (31.549) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.025) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating fairly steady price growth. JNJ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
GSK | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 17 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 5 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 42 | 4 | |
SMR RATING 1..100 | 34 | 37 | |
PRICE GROWTH RATING 1..100 | 56 | 45 | |
P/E GROWTH RATING 1..100 | 56 | 10 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GSK's Valuation (5) in the Pharmaceuticals Major industry is in the same range as JNJ (12). This means that GSK’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (42). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
GSK's SMR Rating (34) in the Pharmaceuticals Major industry is in the same range as JNJ (37). This means that GSK’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Price Growth Rating (45) in the Pharmaceuticals Major industry is in the same range as GSK (56). This means that JNJ’s stock grew similarly to GSK’s over the last 12 months.
JNJ's P/E Growth Rating (10) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (56). This means that JNJ’s stock grew somewhat faster than GSK’s over the last 12 months.
| GSK | JNJ | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 70% | 2 days ago 45% |
| Stochastic ODDS (%) | 2 days ago 32% | 2 days ago 50% |
| Momentum ODDS (%) | 2 days ago 71% | 2 days ago 43% |
| MACD ODDS (%) | 2 days ago 67% | N/A |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 40% |
| TrendMonth ODDS (%) | 2 days ago 53% | 2 days ago 44% |
| Advances ODDS (%) | 2 days ago 63% | 6 days ago 46% |
| Declines ODDS (%) | 9 days ago 55% | 13 days ago 40% |
| BollingerBands ODDS (%) | 2 days ago 73% | 2 days ago 45% |
| Aroon ODDS (%) | 2 days ago 43% | 2 days ago 39% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 1 FA rating(s) are green while JNJ’s FA Score has 3 green FA rating(s).
- GSK’s FA Score: 1 green, 4 red.
- JNJ’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 5 TA indicator(s) are bullish while JNJ’s TA Score has 4 bullish TA indicator(s).
- GSK’s TA Score: 5 bullish, 4 bearish.
- JNJ’s TA Score: 4 bullish, 5 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а +6.47% price change this week, while JNJ (@Pharmaceuticals: Major) price change was -2.25% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.91%. For the same industry, the average monthly price growth was -4.47%, and the average quarterly price growth was +3.55%.
Reported Earning Dates
GSK is expected to report earnings on Oct 28, 2026.
JNJ is expected to report earnings on Jan 26, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (-0.91% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with ABBV. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then ABBV could also see price increases.